Skip to content

Efficacy of Vatantak Gold Tablet and Pain Kill Oil in painful inflammatory Musculoskeletal Conditions

Post-marketing open-label observational clinical study of Vatantak Gold Tablet and Pain Kill Oil in painful inflammatory Musculoskeletal Conditions w.r.t Vatavyadhi

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/11/047342
Enrollment
60
Registered
2022-11-16
Start date
Unknown
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R298- Other symptoms and signs involvingthe nervous and musculoskeletal systems

Interventions

None listed

Sponsors

Med Pharma CRO
Lead Sponsor
Jamna Herbal Research Limited
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients 18 years or older, with musculoskeletal pain. 2.Patients willing to give written informed consent. 3.Patients are fit and no need for any hospital administration. 4.Agree to following instruction of doâ??s and donâ??ts in regular daily lifestyle. 5.Patients willing to perform all study related procedures including the use of study medicine, allow the physical and Biochemical tests and willing to document symptoms and medication.

Exclusion criteria

Exclusion criteria: 1.Use of steroids and/or recreational drugs in the past 6 months. 2.Patients with open wounds or infection at the application site. 3.Patients with renal impairment. 4.Patients will be also excluded if they have poorly controlled diabetes mellitus. 5.Female patients who are pregnant. 6.Unstable medical or psychiatric illness. 7.Chronic & acute disorders requiring hospital admission. 8.Known HIV-positive, Hepatitis B or C status. 9.Inability to carry out visits for the study. 10.Inability to maintain current medication regimen. 11.Inability or unwillingness to participate in all components of the study.

Design outcomes

Primary

MeasureTime frame
1.Pain Score (VAS and NPRS) 2.Disease activity based on questionnaires(QoL) 3.Blood tests: ESR, RA factor, CRP, Serum Uric Acid (At baseline and after 60 days of treatment) Timepoint: At baseline and after 60 days of treatment

Secondary

MeasureTime frame
1. Quality of Life 2. Drug safety: RFT & LFT 3. Incidence of Adverse events (AE) and Serious Adverse Events (SAE) during the study period (From Baseline to 60 days of treatment) Timepoint: From Baseline to 60 days of treatment

Countries

India

Contacts

Public ContactDR PARIKSHIT DEBNATH

Gananath Sen Institute of Ayurvidya and Research

docdebnath84@gmail.com9836675720

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026